NTLA-1001

N/A

Report date: 2025/08/29 17:05:59

Base Information

Drug NameNTLA-1001
Drug Alias NameNTLA-1001
ClassificationCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionTransthyretin inhibitors
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntellia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntellia Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsTransthyretin amyloidosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A